Cargando…

Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay

A novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China in December 2019, causing an ongoing, rapidly spreading global pandemic. Worldwide, vaccination is now expected to provide containment of the novel virus, resulting in an antibody-mediated immunity. To verify this,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietschmann, Jan, Voepel, Nadja, Voß, Leonie, Rasche, Stefan, Schubert, Max, Kleines, Michael, Krause, Hans-Joachim, Shaw, Tamlyn M., Spiegel, Holger, Schroeper, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132704/
https://www.ncbi.nlm.nih.gov/pubmed/34025604
http://dx.doi.org/10.3389/fmicb.2021.643275
_version_ 1783694943612567552
author Pietschmann, Jan
Voepel, Nadja
Voß, Leonie
Rasche, Stefan
Schubert, Max
Kleines, Michael
Krause, Hans-Joachim
Shaw, Tamlyn M.
Spiegel, Holger
Schroeper, Florian
author_facet Pietschmann, Jan
Voepel, Nadja
Voß, Leonie
Rasche, Stefan
Schubert, Max
Kleines, Michael
Krause, Hans-Joachim
Shaw, Tamlyn M.
Spiegel, Holger
Schroeper, Florian
author_sort Pietschmann, Jan
collection PubMed
description A novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China in December 2019, causing an ongoing, rapidly spreading global pandemic. Worldwide, vaccination is now expected to provide containment of the novel virus, resulting in an antibody-mediated immunity. To verify this, serological antibody assays qualitatively as well as quantitatively depicting the amount of generated antibodies are of great importance. Currently available test methods are either laboratory based or do not have the ability to indicate an estimation about the immune response. To overcome this, a novel and rapid serological magnetic immunodetection (MID) point-of-care (PoC) assay was developed, with sensitivity and specificity comparable to laboratory-based DiaSorin Liaison SARS-CoV-2 S1/S2 IgG assay. To specifically enrich human antibodies against SARS-CoV-2 in immunofiltration columns (IFCs) from patient sera, a SARS-CoV-2 S1 antigen was transiently produced in plants, purified and immobilized on the IFC. Then, an IgG-specific secondary antibody could bind to the retained antibodies, which was finally labeled using superparamagnetic nanoparticles. Based on frequency magnetic mixing technology (FMMD), the magnetic particles enriched in IFC were detected using a portable FMMD device. The obtained measurement signal correlates with the amount of SARS-CoV-2-specific antibodies in the sera, which could be demonstrated by titer determination. In this study, a MID-based assay could be developed, giving qualitative as well as semiquantitative results of SARS-CoV-2-specific antibody levels in patient’s sera within 21 min of assay time with a sensitivity of 97% and a specificity of 92%, based on the analysis of 170 sera from hospitalized patients that were tested using an Food and Drug Administration (FDA)-certified chemiluminescence assay.
format Online
Article
Text
id pubmed-8132704
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81327042021-05-20 Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay Pietschmann, Jan Voepel, Nadja Voß, Leonie Rasche, Stefan Schubert, Max Kleines, Michael Krause, Hans-Joachim Shaw, Tamlyn M. Spiegel, Holger Schroeper, Florian Front Microbiol Microbiology A novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China in December 2019, causing an ongoing, rapidly spreading global pandemic. Worldwide, vaccination is now expected to provide containment of the novel virus, resulting in an antibody-mediated immunity. To verify this, serological antibody assays qualitatively as well as quantitatively depicting the amount of generated antibodies are of great importance. Currently available test methods are either laboratory based or do not have the ability to indicate an estimation about the immune response. To overcome this, a novel and rapid serological magnetic immunodetection (MID) point-of-care (PoC) assay was developed, with sensitivity and specificity comparable to laboratory-based DiaSorin Liaison SARS-CoV-2 S1/S2 IgG assay. To specifically enrich human antibodies against SARS-CoV-2 in immunofiltration columns (IFCs) from patient sera, a SARS-CoV-2 S1 antigen was transiently produced in plants, purified and immobilized on the IFC. Then, an IgG-specific secondary antibody could bind to the retained antibodies, which was finally labeled using superparamagnetic nanoparticles. Based on frequency magnetic mixing technology (FMMD), the magnetic particles enriched in IFC were detected using a portable FMMD device. The obtained measurement signal correlates with the amount of SARS-CoV-2-specific antibodies in the sera, which could be demonstrated by titer determination. In this study, a MID-based assay could be developed, giving qualitative as well as semiquantitative results of SARS-CoV-2-specific antibody levels in patient’s sera within 21 min of assay time with a sensitivity of 97% and a specificity of 92%, based on the analysis of 170 sera from hospitalized patients that were tested using an Food and Drug Administration (FDA)-certified chemiluminescence assay. Frontiers Media S.A. 2021-05-05 /pmc/articles/PMC8132704/ /pubmed/34025604 http://dx.doi.org/10.3389/fmicb.2021.643275 Text en Copyright © 2021 Pietschmann, Voepel, Voß, Rasche, Schubert, Kleines, Krause, Shaw, Spiegel and Schroeper. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Pietschmann, Jan
Voepel, Nadja
Voß, Leonie
Rasche, Stefan
Schubert, Max
Kleines, Michael
Krause, Hans-Joachim
Shaw, Tamlyn M.
Spiegel, Holger
Schroeper, Florian
Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title_full Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title_fullStr Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title_full_unstemmed Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title_short Development of Fast and Portable Frequency Magnetic Mixing-Based Serological SARS-CoV-2-Specific Antibody Detection Assay
title_sort development of fast and portable frequency magnetic mixing-based serological sars-cov-2-specific antibody detection assay
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132704/
https://www.ncbi.nlm.nih.gov/pubmed/34025604
http://dx.doi.org/10.3389/fmicb.2021.643275
work_keys_str_mv AT pietschmannjan developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT voepelnadja developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT voßleonie developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT raschestefan developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT schubertmax developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT kleinesmichael developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT krausehansjoachim developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT shawtamlynm developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT spiegelholger developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay
AT schroeperflorian developmentoffastandportablefrequencymagneticmixingbasedserologicalsarscov2specificantibodydetectionassay